Comprehensive Overview of Carbamic acid,(3-aminobutyl)-, phenylmethyl ester (9CI) (CAS No. 885277-99-6)
Carbamic acid,(3-aminobutyl)-, phenylmethyl ester (9CI), with the CAS registry number 885277-99-6, is a specialized organic compound that has garnered significant attention in the fields of medicinal chemistry and biochemical research. This compound, often referred to by its systematic name, belongs to the class of carbamate esters, which are known for their versatile applications in drug design and synthesis. The presence of both amino and ester functional groups in its structure makes it a valuable intermediate for the development of novel therapeutic agents.
In recent years, the demand for carbamate derivatives like Carbamic acid,(3-aminobutyl)-, phenylmethyl ester (9CI) has surged due to their potential in targeting enzyme inhibition and receptor modulation. Researchers are particularly interested in its role as a building block for peptide mimetics and small molecule drugs. The compound's unique structure allows for selective interactions with biological targets, making it a focal point in studies related to neurodegenerative diseases and metabolic disorders.
The synthesis of 885277-99-6 involves multi-step organic reactions, often starting from readily available precursors such as 3-aminobutanol and benzyl chloroformate. The process typically includes protection-deprotection strategies to ensure high yield and purity. Advanced analytical techniques like NMR spectroscopy and mass spectrometry are employed to characterize the compound, ensuring its suitability for further applications. This rigorous quality control aligns with the growing industry emphasis on high-purity intermediates for pharmaceutical development.
One of the most discussed topics in relation to Carbamic acid,(3-aminobutyl)-, phenylmethyl ester (9CI) is its potential in drug discovery pipelines. With the rise of computational chemistry and AI-driven molecular modeling, researchers are increasingly leveraging this compound to explore structure-activity relationships (SAR). Its modular design allows for easy derivatization, enabling the creation of libraries of analogs for high-throughput screening. This aligns with the current trend of precision medicine, where tailored therapeutics are developed for specific patient populations.
From an industrial perspective, 885277-99-6 is often sourced by contract research organizations (CROs) and pharmaceutical manufacturers engaged in custom synthesis. The compound's stability under standard storage conditions (typically at 2-8°C in a dry environment) makes it a practical choice for long-term research projects. Additionally, its compatibility with common organic solvents like dimethyl sulfoxide (DMSO) and methanol facilitates its use in various experimental setups.
Environmental and safety considerations are also critical when working with Carbamic acid,(3-aminobutyl)-, phenylmethyl ester (9CI). While not classified as hazardous under current regulations, proper laboratory handling protocols—including the use of personal protective equipment (PPE)—are recommended. This reflects the broader shift toward green chemistry principles in synthetic organic chemistry, where minimizing waste and optimizing atom economy are prioritized.
Looking ahead, the scientific community anticipates expanded applications for CAS No. 885277-99-6 in emerging fields such as bioconjugation chemistry and prodrug design. Its ability to serve as a linker molecule in antibody-drug conjugates (ADCs) is particularly promising, given the growing interest in targeted cancer therapies. Furthermore, its potential role in sustained-release formulations could address challenges in drug delivery systems.
For researchers seeking detailed information about Carbamic acid,(3-aminobutyl)-, phenylmethyl ester (9CI), authoritative databases like SciFinder and Reaxys provide comprehensive data on its physicochemical properties and synthetic routes. The compound's molecular weight (223.28 g/mol) and logP value (indicative of its lipophilicity) are frequently queried parameters, underscoring the importance of these metrics in drug-likeness assessments.
In conclusion, 885277-99-6 represents a compelling case study in how specialty chemicals drive innovation across multiple scientific disciplines. Its dual functionality as both a research tool and pharmaceutical intermediate ensures its continued relevance in an era marked by rapid advancements in biotechnology and personalized healthcare. As synthetic methodologies evolve and analytical capabilities expand, this compound is poised to play an even greater role in shaping the future of bioactive molecule development.
